300482 万孚生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,690,175-22.52%3,064,8092,764,9145,680,5133,361,043
减:营业总成本1,602,538-6.60%2,433,9642,294,6514,330,0262,756,369
    其中:营业成本671,032-15.88%1,098,8801,033,7712,736,6261,396,076
               财务费用28,47797.76%2,219(6,405)(698)48,921
               资产减值损失(7,835)--(12,403)(11,522)(78,975)(5,874)
公允价值变动收益25,0532.57%29,61814,79912,81210,551
投资收益13,745599.85%1,92031,10059,77347,468
    其中:对联营企业和合营企业的投资收益(9,336)-24.85%(29,010)(4,333)3,2391,263
营业利润129,744-73.95%636,845549,1381,367,732691,897
利润总额126,620-74.31%629,463540,7631,364,526680,489
减:所得税费用185-99.65%64,24753,334174,40647,908
净利润126,435-71.25%565,215487,4281,190,120632,580
减:非控股权益(7,305)-288.25%3,587(196)(6,943)(1,853)
股东净利润133,740-69.32%561,629487,6251,197,063634,433

市场价值指针
每股收益 (元) *0.280-70.21%1.2101.1002.7101.430
每股派息 (元) *----0.4000.4000.5000.300
每股净资产 (元) *11.5213.43%11.3149.9179.5307.294
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容